Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare disease that is defined as biallelic mutations of ADAMTS13 causing persistent absence of ADAMTS13 activity. The confirmed diagnosis requires a genetic study, and cTTP has never been previously reported in Taiwan. Our patient was a 29-year-old Taiwanese woman who presented with severe hyperbilirubinemia at birth. She had severe thrombocytopenia and hemolytic anemia at the age of 1, and another acute TTP event at the age of 7 triggered by an upper airway infection. Regular plasma replacement was started at age 12 based on a presumptive diagnosis of cTTP. Clinical diagnosis of cTTP, with undetectable ADAMTS13 activity and absence of ADAMTS13 inhibitor, was confirmed at age 27. A genetic study showed a previously reported mutation c.1921G to A, inherited from her father, and a maternally inherited, novel mutation at exon 12, c.1435+1dupG, which results in a splicing site change and frame shift. Reports of cTTP from East Asia, except Japan, are scarce. Some prevalent ADAMTS13 mutations are also race or region specific. With this report, we hope to raise awareness among physicians in Taiwan, promote early, proper diagnosis of cTTP, and reveal the true prevalence of cTTP in the Taiwanese population.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-03068-5DOI Listing

Publication Analysis

Top Keywords

diagnosis cttp
12
congenital thrombotic
8
thrombotic thrombocytopenic
8
thrombocytopenic purpura
8
novel mutation
8
absence adamts13
8
adamts13 activity
8
genetic study
8
cttp
7
adamts13
6

Similar Publications

Congenital thrombotic thrombocytopenic purpura (cTTP) is a thrombotic microangiopathy (TMA) characterized by severe hereditary ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) deficiency caused by mutations. This rare autosomal recessive genetic disorder is often misdiagnosed as immune thrombocytopenia (ITP) or hemolytic uremic syndrome (HUS). Here, we report a 21-year-old male cTTP patient with a compound heterozygous mutation.

View Article and Find Full Text PDF

[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?].

Dtsch Med Wochenschr

November 2024

Klinik für Innere Medizin I - Abteilung für Hämatologie und Hämostaseologie, Medizinische Universität Wien, Österreich.

100 years ago Dr. Eli Moschcowitz described the first case of thrombotic thrombocytopenic purpura. For many decades there were no recognized treatment options, and the mortality rate was extremely high.

View Article and Find Full Text PDF

In the 100 years since Eli Moschcowitz reported the first case of thrombotic thrombocytopenic purpura (TTP), there has been remarkable awareness and progress in the diagnosis and management of this rare blood disorder. This progress initially was the result of careful clinical observations followed by well thought-out therapeutic interventions, with dual goals of both improving outcomes and discerning the pathophysiology of TTP. The discovery of the ADAMTS13 protease set in motion the efforts to more accurately define the specific etiologies of thrombotic microangiopathies (TMAs) based on objective, scientific data rather than clinical characterizations alone.

View Article and Find Full Text PDF
Article Synopsis
  • * Congenital thrombotic thrombocytopenic purpura (cTTP) was suspected, prompting tests for ADAMTS13 activity, which revealed severely decreased activity but no inhibitors present.
  • * The combination of test results and genetic testing in her family confirmed a diagnosis of cTTP, highlighting the need for careful evaluation of ITP patients for potential cTTP during follow-up.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!